cerebral adrenoleukodystrophy

The European Commission has granted marketing authorisation for NEZGLYAL, the first pharmacological treatment for childhood cerebral adrenoleukodystrophy (cALD), a rare and severe genetic brain disorder. Until now, treatment options were largely limited to stem cell transplantation and supportive care. The approval offers a new therapy option for patients across the EU and is being noted in rare disease and biotech circles.